Isabel Gonzalez-Mariscal
Overview
Explore the profile of Isabel Gonzalez-Mariscal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
414
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wreven E, Ruiz de Adana M, Hardiville S, Gmyr V, Kerr-Conte J, Chetboun M, et al.
Diabetologia
. 2025 Feb;
PMID: 39954060
No abstract available.
2.
Wreven E, Ruiz de Adana M, Hardiville S, Gmyr V, Kerr-Conte J, Chetboun M, et al.
Diabetologia
. 2024 Jun;
67(9):1877-1896.
PMID: 38864887
Aims/hypothesis: Insulitis, a hallmark of inflammation preceding autoimmune type 1 diabetes, leads to the eventual loss of functional beta cells. However, functional beta cells can persist even in the face...
3.
Ruiz-de-Adana M, Dominguez M, Morillas V, Colomo N, Vallejo-Mora R, Guerrero M, et al.
Diabetes Res Clin Pract
. 2024 Mar;
210:111620.
PMID: 38514300
No abstract available.
4.
Aseer K, Mazucanti C, OConnell J, Gonzalez-Mariscal I, Verma A, Yao Q, et al.
Mol Metab
. 2024 Mar;
82:101917.
PMID: 38499184
No abstract available.
5.
Aseer K, Mazucanti C, OConnell J, Gonzalez-Mariscal I, Verma A, Yao Q, et al.
Mol Metab
. 2024 Feb;
82:101906.
PMID: 38423253
Objective: Type 1 diabetes (T1D) occurs because of islet infiltration by autoreactive immune cells leading to destruction of beta cells and it is becoming evident that beta cell dysfunction partakes...
6.
Lhamyani S, Gentile A, Mengual-Mesa M, Grueso E, Giraldez-Perez R, Fernandez-Garcia J, et al.
Biomed Pharmacother
. 2024 Jan;
171:116104.
PMID: 38198956
Despite the abundance of registered clinical trials worldwide, the availability of effective drugs for obesity treatment is limited due to their associated side effects. Thus, there is growing interest in...
7.
Ruiz de Adana M, Dominguez M, Morillas V, Colomo N, Vallejo-Mora R, Guerrero M, et al.
Diabetes Res Clin Pract
. 2023 Jan;
196:110238.
PMID: 36610544
Aims: To compare efficacy and safety of degludec 100 IU/mL (Deg-100) and glargine 300 IU/mL (Gla-300) in adults with type 1 diabetes. Methods: Open-label, single-center, randomized, parallel-group, 24-week trial in...
8.
Gonzalez-Mariscal I, Pozo-Morales M, Romero-Zerbo S, Espinosa-Jimenez V, Escamilla-Sanchez A, Sanchez-Salido L, et al.
Biomed Pharmacother
. 2021 Dec;
145:112361.
PMID: 34872800
The atypical cannabinoid Abn-CBD improves the inflammatory status in preclinical models of several pathologies, including autoimmune diseases. However, its potential for modulating inflammation in autoimmune type 1 diabetes (T1D) is...
9.
Carmona-Hidalgo B, Garcia-Martin A, Munoz E, Gonzalez-Mariscal I
Pharmaceuticals (Basel)
. 2021 Sep;
14(9).
PMID: 34577563
Anti-inflammatory and antidiabetogenic properties have been ascribed to cannabidiol (CBD). CBD-based medicinal drugs have been approved for over a lustrum, and a boom in the commercialization of CBD products started...
10.
Gonzalez-Mariscal I, Carmona-Hidalgo B, Winkler M, Unciti-Broceta J, Escamilla A, Gomez-Canas M, et al.
Pharmacol Res
. 2021 May;
169:105492.
PMID: 34019978
Natural cannabidiol ((-)-CBD) and its derivatives have increased interest for medicinal applications due to their broad biological activity spectrum, including targeting of the cannabinoid receptors type 1 (CBR) and type...